6533b86efe1ef96bd12cb42f
RESEARCH PRODUCT
Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyltransferase.
Peter FischerJürgen E. ScherberichStephan StörkelWinfried Haasesubject
Cancer ResearchPathologymedicine.medical_specialtymedicine.drug_classImmunologyHistogenesisBiologyurologic and male genital diseasesMonoclonal antibodyKidneyEpitopeEpitheliumDiagnosis DifferentialImmunoenzyme TechniquesFetusCarcinomamedicineImmunology and AllergyHumansMicroscopy ImmunoelectronKidneyCancerAntibodies Monoclonalgamma-GlutamyltransferaseClinical Enzyme Testsmedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureOncologyImmunohistochemistryDifferential diagnosisdescription
The localization of membrane-bound gamma-glutamyltransferase with monoclonal antibody (mAb) 138H11 proved to be of value for differential diagnosis of renal cancer, since it correlated with the histogenetic profile of human epithelial renal tumors. Immunoreactive gamma-glutamyltransferase was located in the proximal tubule in all normal human kidneys (15/15) examined thus far by both ultrastructural and immunohistochemical techniques. From 68 epithelial renal cancers tested 31/31 clear-cell carcinomas and 15/16 chromophilic carcinomas expressed the target epitope of mAb 138H11. In contrast, 0/11 oncytomas, 0/9 chromophobic carcinomas, and 0/1 Duct-Bellini carcinoma were immunoreactive. These results support a model of histogenesis and classification of epithelial renal tumours, according to which clear-cell and chromophilic renal carcinomas originate from transformed proximal tubule cells, whereas oncocytomas, chromophilic and Duct-Bellini carcinomas originate from cells of the collecting duct.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1991-11-01 | Cancer immunology, immunotherapy : CII |